Showing 2911-2920 of 5621 results for "".
- Oculis Prices $110 Million Financing to Accelerate Privosegtor Developmenthttps://modernod.com/news/oculis-prices-110-million-financing-to-accelerate-privosegtor-development/2484298/Oculis announced the pricing of offerings of an aggregate of 5,432,098 of its ordinary shares at a price of $20.25 per share for total gross proceeds of $110 million. The net proceeds from the financing will be used to advance and accelerate the d
- Regeneron Delays Regulatory Submission for Eylea HD Pre-Filled Syringe After CRLhttps://modernod.com/news/regeneron-delays-regulatory-submission-for-eylea-hd-pre-filled-syringe-after-crl/2484294/In its third quarters earnings filing, Regeneron said it received another complete response letter (CRL) from the FDA for its pre-filled syringe supplemental BLA (sBLA) for Eylea HD (aflibercept injection 8 mg). The sole approvability issue cited in the CRL relates to unresolved inspection findin
- OneSight EssilorLuxottica Foundation and Vision To Learn Extend Partnership to Expand Vision Care for Children Nationwidehttps://modernod.com/news/onesight-essilorluxottica-foundation-and-vision-to-learn-extend-partnership-to-expand-vision-care-for-children-nationwide/2484209/The OneSight EssilorLuxottica Foundation and Vision To Learn announced a 2-year extension of their 8-year partnership dedicated to providing vision care services to children in need—helping them see clearly and reach their full potential in school and be
- Astellas Announces New Data Demonstrating Long-Term Efficacy of Izervay in Slowing GA Progressionhttps://modernod.com/news/astellas-announces-new-data-demonstrating-long-term-efficacy-of-izervay-in-slowing-ga-progression/2484199/Astellas Pharma announced the first results from the open-label extension (OLE) trial of the phase 3 GATHER2 study, which showed that monthly treatment with Izervay (avacincaptad pegol intravitreal solution) continued to slow disease progression in patie
- Sight Sciences Announces Fee Schedule Establishment for TearCare Dry Eye Procedurehttps://modernod.com/news/sight-sciences-announces-fee-schedule-establishment-for-tearcare-dry-eye-procedure/2484193/Sight Sciences announced that two Medicare Administrative Contractors (MACs), Novitas Solutions and First Coast Service Options (FCSO), each established jurisdiction-wide pricing for CPT code 0563T (evacuation of meibomian glands, using heat delivered through wearable, open-eye eye
- Formycon Expands Global Reach of Eylea Biosimilar FYB203 with Licensing Deals in Australia and Latin Americahttps://modernod.com/news/formycon-expands-global-reach-of-eylea-biosimilar-fyb203-with-licensing-deals-in-australia-and-latin-america/2484186/Formycon AG announced that its licensing partner Klinge Biopharma, the exclusive global commercialization rights holder for Formycon’s Eylea¹ biosimilar FYB203 (aflibercept), has signed two new exclusive agreements to broaden the product’s internat
- Heidelberg and NetraMind Collaborate to Deliver AI-Powered Choroid Analysis on AppWay Marketplacehttps://modernod.com/news/heidelberg-and-netramind-collaborate-to-deliver-ai-powered-choroid-analysis-on-appway-marketplace/2484166/Heidelberg Engineering announced a new collaboration with NetraMind Innovations, an AI-driven image analysis software company founded by retinal specialists and machine learning engineers. Their new application, NMI-ChoroidAI,* is now available via the Heidelb
- Visionix USA to Debut VX 40 Couture Auto Lensmeter at Vision Expo Westhttps://modernod.com/news/visionix-usa-to-debut-vx-40-couture-auto-lensmeter-at-vision-expo-west/2484141/Visionix USA will unveil its latest innovation—the VX 40 Couture—at Vision Expo West, September 18–21 at the Venetian Expo Center in Las Vegas. According to Visionix, the VX 40 Couture is a next-
- Nanoscope Secures EMA Orphan Designations and FDA RMAT Status for Retinal Gene Therapy MCO-010https://modernod.com/news/nanoscope-secures-ema-orphan-designations-and-fda-rmat-status-for-retinal-gene-therapy-mco-010/2484130/Nanoscope Therapeutics announced regulatory milestones in both Europe and the United States for its lead gene therapy candidate, MCO-010 (sonpiretigene isteparvovec). The European Medicines Agency (EMA) has granted Orphan D
- Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space Delivery Platformhttps://modernod.com/news/clearside-biomedical-announces-plan-to-explore-strategic-alternatives-to-advance-its-proprietary-suprachoroidal-space-delivery-platform/2482892/Clearside Biomedical announced it has initiated a formal process to explore a range of strategic alternatives aimed at maximizing shareholder value and advancing its pipeline. To support this initiative, Clearside has